Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin Newborn Screening Panel

This publication has 18 references indexed in Scilit:

• Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Mutations Identified by MS/MS-Based Prospective Screening of Newborns Differ from Those Observed in Patients with Clinical Symptoms: Identification and Characterization of a New, Prevalent Mutation That Results in Mild MCAD Deficiency*
  American Journal of Human Genetics, 2001
• Willingness to Pay for a Quality-adjusted Life Year
  Medical Decision Making, 2000
• Automated Tandem Mass Spectrometry for Mass Newborn Screening for Disorders in Fatty Acid, Organic Acid, and Amino Acid Metabolism
  Journal of Child Neurology, 1999
• Medium chain acyl-CoA dehydrogenase deficiency: Human genome epidemiology review
  Genetics in Medicine, 1999
• Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis
  Archives of Disease in Childhood, 1999
• Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK
  Archives of Disease in Childhood, 1998
• Regional variations in medium-chain acyl-CoA dehydrogenase deficiency
  The Lancet, 1995
• Medium–chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children
  The Journal of Pediatrics, 1994
• Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: The Prevalent Mutation G985 (K304E) Is Subject to a Strong Founder Effect from Northwestern Europe
  Human Heredity, 1993
• Cost and health implications of cholesterol lowering.
  Circulation, 1992